City

Seoul (1)

Condition

PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment (1)

Overall Status

Recruiting (1)

Sign in for free

Phase

phase 2 (1)

Sponsor

Yonsei University (1)

Collaborator

CanariaBio Inc. (1)

Intervention

orevogomab+pld (1)

Study Documents

Intervention Type

drug (1)

Funder Type

Other (1)

Study Type

Interventional (1)

parp inhibitor resistant ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment

Showing 1 - 1 of 1

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment

Recruiting

PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment

Orevogomab+PLD

Seoul, Korea, Republic of

Yonsei University Health System, Severance Hospital

Dec 4, 2022